Next-Generation Platforms for Vaccine Design and Immune Evaluation

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccine Design, Development, and Delivery".

Deadline for manuscript submissions: 31 July 2026 | Viewed by 1638

Special Issue Editors


E-Mail Website
Guest Editor
Department of Drug Sciences, Università degli Studi di Catania, Catania, Italy
Interests: vaccine design; mRNA vaccines; computational modeling; bioinformatics

E-Mail Website
Guest Editor
Department of Drug Sciences, Università degli Studi di Catania, Catania, Italy
Interests: vaccine design; computational modeling; bioinformatics; systems immunology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The rapid development of new vaccine technologies, particularly during the COVID-19 pandemic, has underscored the transformative potential of innovative platforms in global health. Among these, mRNA-based vaccines, viral vectors, peptide and multi-epitope constructs, and nanoparticle delivery systems have opened new avenues for rational vaccine design and accelerated development timelines. At the same time, computational modeling, bioinformatics pipelines, and artificial intelligence tools are increasingly being integrated into the vaccine discovery process, enabling more accurate epitope prediction, optimization of antigen design, and in silico simulations of immune responses.

Despite these advances, several challenges remain, including the need to improve immunogenicity, ensure long-term protection, and understand the complexity of host–pathogen interactions. The integration of innovative vaccine platforms with comprehensive immunological evaluation—ranging from in silico models and omics-driven profiling to experimental and clinical validation—offers an unprecedented opportunity to address these gaps.

To achieve a more extensive understanding of recent scientific knowledge and current trends in this field, this Special Issue will focus on recent progress in novel vaccine platforms and immunological evaluation strategies. Based on your expertise and research, we invite you to contribute original research articles, reviews, or short communications, covering (i) the design and optimization of next-generation vaccines, (ii) computational and AI-driven approaches for vaccine development, (iii) nanoparticle and delivery technologies, (iv) systems immunology and omics-based evaluation of vaccine responses, and (v) translational and clinical perspectives in vaccine innovation.

Dr. Valentina Di Salvatore
Dr. Giulia Russo
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • vaccine design
  • mRNA vaccines
  • computational modeling
  • immunoinformatics
  • systems immunology
  • nanoparticle-based delivery
  • immunological evaluation

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

22 pages, 1409 KB  
Review
Targeting the MR1-MAIT Cell Axis for Vaccination Against Infectious Disease
by Mattie S. M. Timmer, Lisa M. Connor and Bridget L. Stocker
Vaccines 2026, 14(2), 117; https://doi.org/10.3390/vaccines14020117 - 26 Jan 2026
Viewed by 1137
Abstract
Mucosal-associated invariant T (MAIT) cells exist in high numbers in the body and have a unique and highly conserved T cell receptor (TCR). They can be activated in a TCR-dependent manner by ligands presented on the monomorphic protein MHC class I-related protein 1 [...] Read more.
Mucosal-associated invariant T (MAIT) cells exist in high numbers in the body and have a unique and highly conserved T cell receptor (TCR). They can be activated in a TCR-dependent manner by ligands presented on the monomorphic protein MHC class I-related protein 1 (MR1) which is found on many cell types, including professional antigen presenting cells (APCs) and epithelial cells. This has sparked interest in the potential to exploit the MR1-MAIT cell axis for the development of vaccines against infectious disease. Within this context an MR1 ligand, typically 5-(2-oxopropylideneamino)-d-ribitylaminouracil (5-OP-RU), is administered with or without a Toll-like receptor (TLR) ligand or cytokine in a pan vaccination approach that would prime the immune response to provide protection against a variety of bacterial and viral pathogens. This strategy has led to enhanced protection in murine models of Legionella longbeachae, Francisella tularensis, Klebsiella pneumoniae, Streptococcus pneumoniae and influenza infection. However, studies against Mycobacterium tuberculosis infection have proven less successful. The second vaccination approach involves pairing the MR1 ligand with more conventional antigens that could activate CD4+ and/or CD8+ T cells. This approach has been successful in murine models of cholera, influenza, and SARS-CoV-2, including in the context of subunit vaccines. However, there are several challenges when using MR1-MAIT cell-mediated vaccine adjuvants. These include the inherent instability of 5-OP-RU and the need for more advanced studies to better understand how the use of MR1 ligands would translate to applications in humans. This review will discuss these aspects and highlight the mechanistic studies that have been undertaken to understand how MAIT cells might elicit their effects within the context of MAIT cell-mediated vaccines for infectious disease. Full article
(This article belongs to the Special Issue Next-Generation Platforms for Vaccine Design and Immune Evaluation)
Show Figures

Figure 1

Back to TopTop